Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designing and implementing a prediabetes screening in community pharmacies and online prevention program: findings from the PREDICT study.

BMC public health·2026
Same author

Self-Management of Medications During Sick Days for Chronic Conditions: A Scoping Review.

Medicina (Kaunas, Lithuania)·2025
Same author

Utilization and effectiveness of nutrition resources in primary healthcare settings: a systematic search and review.

The International journal of pharmacy practice·2025
Same author

Australian pharmacists' experiences and perspectives in implementing a chronic kidney disease screening service in community pharmacies: A qualitative study.

Exploratory research in clinical and social pharmacy·2025
Same author

Developing consensus on the competency and assessment of pharmacist preceptors.

BMC medical education·2025
Same author

Nutrition counseling in pharmacy practice in Australia: A mixed methods study.

Currents in pharmacy teaching & learning·2025

Related Experiment Video

Updated: Jun 1, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

General practitioner-pharmacist interactions in professional pharmacy services.

Connie Van1, Bernadette Mitchell, Ines Krass

  • 1Faculty of Pharmacy, University of Sydney, Sydney, Australia. cvan3116@uni.sydney.edu.au

Journal of Interprofessional Care
|June 11, 2011
PubMed
Summary

Community pharmacies in Australia provide professional pharmacy services (PPS), increasing pharmacist-GP interactions. Environmental factors like protocols and remuneration significantly enhance this collaboration.

More Related Videos

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

Related Experiment Videos

Last Updated: Jun 1, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

Area of Science:

  • Pharmacy Practice
  • Primary Care Collaboration
  • Health Services Research

Background:

  • Australian community pharmacies deliver professional pharmacy services (PPS), including Home Medicines Review (HMR) and Diabetes Medication Assistance Service (DMAS).
  • The level of interaction and collaboration between general practitioners (GPs) and pharmacists within these services remains largely unexamined.

Purpose of the Study:

  • To investigate the nature and extent of interactions between GPs and community pharmacists.
  • To identify factors influencing these interactions within the context of professional pharmacy services.

Main Methods:

  • Conducted individual, semi-structured interviews with 15 GPs and 15 pharmacists.
  • Utilized a purposive sampling strategy across rural and metropolitan areas of New South Wales, Australia.

Main Results:

  • Participation in PPS was perceived to increase the frequency of interactions between pharmacists and GPs.
  • Identified interactional, practitioner, and environmental determinants influencing collaborative behavior.
  • Highlighted specific environmental facilitators: established rules/protocols, interprofessional continuing education, and adequate remuneration.

Conclusions:

  • Enhancing collaboration in PPS requires addressing environmental factors alongside established interactional and practitioner determinants.
  • Focusing on environmental facilitators can improve the effectiveness of primary care collaboration within professional pharmacy services.